2 ASX healthcare stocks, analysts expect firming up

These two ASX healthcare stocks appear well positioned for strong future performance, supported by powerful industry tailwinds and expanding clinical programs. 

2 Best ASX healthcare stocks

Mesoblast Limited (ASX: MSB) 

Clinuvel Pharmaceuticals Limited (ASX: CUV)

Mesoblast Limited (ASX: MSB) 

has strengthened its position in allogeneic cellular medicines which is supported by rising commercial uptake of its FDA approved therapy Ryoncil.
Data presented at the February 2026 Tandem Meetings showed strong survival outcomes in both children and adults with steroid refractory acute graft versus host disease which supports earlier treatment use and expansion into the larger adult segment.

The company plans to begin a pivotal Phase 3 trial in adults with severe SR aGvHD which if successful could allow a label extension and widen the addressable market.
The December 2025 quarter marked a clear improvement as Ryoncil gross sales reached US$35 million and net revenue came in at US$30 million which represents a 60% rise from the previous quarter.

Cash and cash equivalents cam at US$130 million at quarter end while total available funding was close to US$180 million including undrawn facilities which provides about 11.6 quarters of runway.
The company has got a positive FDA feedback on potential filing pathways for rexlemestrocel-L in chronic low back pain which supports regulatory clarity while the confirmatory Phase 3 trial across U.S. sites has progressed as planned.

Clinuvel Pharmaceuticals Limited (ASX: CUV)

has followed a disciplined commercial strategy and its flagship product SCENESSE has demonstrated long-term safety in erythropoietic protoporphyria which is supported by more than two decades of follow up data and high patient retention rate.

Total revenue for FY25 increased 10% to $105.3 million while net profit after tax rose 2% to $36.2 million and cash reserves grew 22% to $224.1 million.
The vitiligo program is progressing with topline results from the Phase III CUV105 study expected in the second half of 2026 while preparations are in place to begin the CUV107 trial.

Management estimates a large U.S. market opportunity in vitiligo which is supported by commercial infrastructure trained centres and reimbursement strategies that are being prepared ahead of potential approvals.

The company has also expanded into central nervous system indications with NEURACTHEL and continues to develop controlled release peptide platforms which broadens the overall pipeline.
Clinuvel has stated it has sufficient funds to run its development programs through to 2028 which reduces funding risk during the clinical expansion phase.

The current market capitalisation is $553.21 million and Clinuvel offers exposure to sustained profitability and expanding clinical programs while its integrated model provides a structural competitive advantage over many development stage peers.

(Source: Company Announcements)